« Pyridines and Dichloromethane |
| Ang. Chem. Gets Weirder Every Day »
May 20, 2010
Astellas and OSI: Nothing like MLNM/Takeda?
Well, here's an advantage of writing a blog: I can go with items like these. A source I have no reason to doubt has heard that high-level people at OSI are saying that the Astellas deal is not exactly going like the Takeda/Millennium deal, at least so far. In Takeda's case, they came in with assurances that they wanted to keep Millennium, that there would be retention bonuses for its people, and so on. Nothing like this has been brought up by Astellas.
In fact, the impression that I'm getting is that no one knows what's going to happen at all. Nothing seems to be known about the fate of OSI's site or its staff - and given that Astellas spent some time pursuing them, you'd think that they'd be more prepared (one way or another) to say what's going on.
This isn't to say that the worst is going to happen - I don't know that at all. It's just that in the absence of any concrete information from the acquiring company, people who have just been acquired are free to assume all kinds of things, which doesn't make for much of a constructive work environment, does it? If and when anyone hears differently, please let me know, and I'll be glad to update things. But for now, I'm sticking with what I've heard: that no one has heard a thing, including some people who really think that they should have by now.
+ TrackBacks (0) | Category: Business and Markets
POST A COMMENT
- RELATED ENTRIES
- Dr. Gilman's Turn Toward the Inside
- Stapled Peptides Take a Torpedo
- Mipomersen In Trouble
- LaMattina on Angell
- The Merck Index
- Asking the Tough Questions: Doomsday in the Clinic
- Don't Let the Art Director Draw Your Molecules
- Rheumatoid Arthritis Wins A Couple of Rounds